# Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Source: https://onco.cc/trials/nct04787042/  
OnCo record `nct04787042` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Obinutuzumab, Pembrolizumab in melanoma and renal cell carcinoma, run by Simcha IL-18, Inc., now recruiting.

## Summary

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 is a phase 1/2 interventional study registered as NCT04787042 by Simcha IL-18, Inc., with 316 participants planned, started 2021-08-06 and due to reach its primary completion in 2025-06-30. Interventions recorded: ST-067, Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA], pembrolizumab. Conditions listed: Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04787042
- Phase: 1/2
- Setting: A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies
- Sponsor: Simcha IL-18, Inc.
- Enrolled: 316

## Sources

- ClinicalTrials.gov NCT04787042: https://clinicaltrials.gov/study/NCT04787042

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct04787042.json